Eli Lilly (LLY) Q3 2024 Earnings
Eli Lilly reported Q3 2024 revenue of $11.4B, missed analyst consensus of $12.1B by $658.7M. Diluted EPS came in at $1.18, missed the $1.47 consensus by $0.29. Eli Lilly reports across 4 business segments, led by Cardiometabolic Health, Oncology, and Immunology.
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about Eli Lilly's Q3 2024 earnings report.
Eli Lilly (LLY) reported Q3 2024 earnings on October 30, 2024 before market open.
Eli Lilly reported revenue of $11.4B and diluted EPS of $1.18 for Q3 2024.
Revenue missed the consensus estimate of $12.1B by $658.7M. EPS missed the consensus estimate of $1.47 by $0.29.
You can read the 10-Q periodic report (0000059478-24-000245) directly on SEC EDGAR. The filing index links above go to sec.gov.